
NHS to fund abiraterone for thousands of high‑risk prostate cancer patients in England
England will start funding the prostate cancer drug abiraterone on the NHS for high‑risk patients whose cancer hasn’t spread, expanding access to about 7,000 men a year and potentially saving hundreds of lives after years of campaigning and supportive trial data from STAMPEDE; the treatment will be available within weeks.











